Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06669234
PHASE1

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

Sponsor: Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

This clinical research trial will evaluate the safety and tolerability of an experimental drug, ALN-F1202, in healthy participants. The purpose of this trial is to learn about how safe and tolerable the experimental drug is. The trial is looking at several other research questions, including: * What side effects may happen from taking the experimental drug? * How much experimental drug is in the blood at different times? * Whether the body makes antibodies against the experimental drug (which could make the drug less effective or could lead to side effects). * What is the best dose of the experimental drug?

Official title: A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ALN-F1202, an siRNA Against Factor XII, in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

56

Start Date

2025-03-06

Completion Date

2026-07-30

Last Updated

2026-02-23

Healthy Volunteers

Yes

Interventions

DRUG

ALN-F1202

Administered per the protocol

DRUG

Matching Placebo

Administered per the protocol

Locations (1)

Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)

Leuven, Vlaams-Brabant, Belgium